Healthcare Industry - Medical - Pharmaceutical - Biotech in Boston, United States

iPharma Expo 2024, USA (International Pharmaceutical Business Expo 2024) scheduled during August 16- 17, 2024 , at Boston, USA. This expo will showcase the latest trends and technologies in pharmaceuticals, drugs and formulations and will bring together eminent perso ..

DCTs were proclaimed as the silver bullet during the pandemic, but it is now clear that they are not as cheap or easy as expected. The 5th Optimizing Hybrid Clinical Trials Summit is uniting stakeholders in Clinical Operations, Innovation, Procurement and Digital ..

The Computational RNA Design and Delivery Summit is the world's only technical and industry-dedicated forum shining light onto the digital age using artificial intelligence, deep neural networks, language models, and predictive algorithms to unlock the black box of d ..

In an era marked by remarkable advancements, the inhalation therapy field is rapidly evolving. From Avalyn's $175 million investment in inhaled pulmonary fibrosis trials to Krystal Biotech's FDA clearance for inhaled gene therapy and MIT engineers' work on inhaled na ..

Engineering Safety and Developability for Complex Antibody-Based Therapeutics. The Antibody and Fusion Protein Engineering and Developability Summit returns as the protein developers' playbook on selecting and engineering the billion-dollar candidate, that can pai ..

Positioned in the goldilocks spot between small molecules and biologics, peptide therapeutics have undergone an exciting uphill trajectory within the last decade. Fuelled by advances in synthesis and screening technologies, together with novel design and delivery str ..

After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in cognitive decline receiving the green light from the FDA and PMDA and Eli Lilly's Donanemab ..

As cell therapy trials advance, creating a simplified, efficient, and harmonized supply chain has never been more significant to prepare for scaling up the supply chain as you develop to the next stage of your cell therapy pipeline. Uniting supply chain and clinic ..

This conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. Additionally, this meeting also showcases ground-b ..

Neuroimmunology discovery has continued to expand over the past year, with emerging and continued biology and target investigation against TREM2, RIPK1, ferroptosis, NLRP3, LRRK2, and beyond. However, there are still significant translational barriers to overcome to ..

Conference Name: BioClina 2024 – International Conference on Biological & Clinical Studies, 13-14 March, Boston Conference Dates: 13-14 March 2024 Conference Application Form: https://hbsra.org/online-application?association=teaching-and-education-research-asso ..

Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and Formats Traditional ADCs have seen significant success in recent years, but still face many challenges, from limited payloa ..

With the number of new clinical ADC targets reaching an all-time high, the 3rd ADC Target Selection Summit returns as the only industry-specific meeting spotlighting the latest developments in the field that will continue progressing first- and best-in-class ADCs thr ..

The 4th Annual CRISPR 2.0 Congress will represent the next frontier in the cell and gene therapy landscape. This event will showcase the latest and greatest CRISPR tools that are being developed and applied in therapeutic areas to translate to safer, more precise, an ..

Drawing on our established 5-year events in the series, the 6th LAFM returns for more content, new case-studies, 50+ speakers, and a brand-new track. As the only peer led community for R and D operations leaders, from large pharma to start-ups, LAFM is your networ ..

Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development. As regulators scrutinize products more closely, accurately characterizing gene therap ..

As the first and only industry-led forum dedicated to tackling the most pressing challenges when delivering RNA-based drugs, the 2nd Annual Non-Viral RNA Delivery Systems Summit is set to unite 50+ key thought leaders in biopharma and academia eager to help RNA vacci ..

There's significant momentum in the clinical and preclinical pipeline for dry AMD, backed by record-breaking investments and acquisitions. This was further demonstrated by the landmark first approval in February this year. The question for the field now is - what's n ..

Accelerating Patient Access to Early and Affordable Detection and Surveillance Tests The 2nd Liquid Biopsy Surveillance and Early Detection Summit returns as industry's only meeting showcasing biopharma-led case studies and assay developer technical progress to cr ..

Despite a challenging 2022 for Gene Therapy developers targeting the CNS, the recent approvals of Skysona by bluebird bio and Upstaza by PTC Therapeutics have validated the potential that gene therapies can act as transformative medicines within the CNS community. ..

The Dermatology Drug Development Summit returns for its 7th year as the largest industry focused summit dedicated to advancing treatment options across Atopic Dermatitis, Alopecia Areata, Hidradenitis suppurativa, Prurigo Nodularis and Vitiligo to name a few. From ..

This Fall, the world's longest-standing and most comprehensive TPD meeting, the 6th TPD Summit, returns to Boston in 2023 as the trusted, definitive, end-to-end forum for the global network of protein degradation drug developers. Ensure your whole team stays connect ..

The HER2 space continues to storm ahead of other oncology fields due to the overwhelming success of Enhertu and the continued satisfaction with Herceptin. As we enter 2023, the field shows no sign of slowing down and it is turning its attention to non-breast cancer t ..